NTILF (Neurotech International) Shares Outstanding (EOP): 1,049.62 Mil (As of Dec. 2025)


NTILF Neurotech International Ltd NTILF
34 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Neurotech International Shares Outstanding (EOP)?

Neurotech International NTILF 34 Shares Outstanding (EOP) is 1,049.62 Mil as of Dec. 2025. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Neurotech International's shares outstanding for the quarter that ended in Dec. 2025 was 1,049.62 Mil.

Neurotech International's quarterly shares outstanding stayed the same from Jun. 2025 (1,049.62 Mil) to Dec. 2025 (1,049.62 Mil).

Neurotech International's annual shares outstanding increased from Jun. 2024 (1,017.39 Mil) to Jun. 2025 (1,049.62 Mil). It means Neurotech International issued new shares from Jun. 2024 to Jun. 2025 .


Neurotech International  (OTCPK:NTILF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Neurotech International Shares Outstanding (EOP) Related Terms


Neurotech International Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Neurotech International's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurotech International Shares Outstanding (EOP) Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 696.82 697.70 873.91 1,017.39 1,049.62

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 891.74 1,017.39 1,042.12 1,049.62 1,049.62

NTILF vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Neurotech International's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurotech International Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurotech International's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Neurotech International's Shares Outstanding (EOP) falls into.


NTILF
34GF Score
Neurotech International Ltd NTILF
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurotech International Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 1,049.62 Mil mean?
Neurotech International (NTILF) has a Shares Outstanding (EOP) of 1,049.62 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Neurotech International and its competitors.
Is Neurotech International's Shares Outstanding (EOP) too high?
Neurotech International's current Shares Outstanding (EOP) is 1,049.62 Mil. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's Shares Outstanding (EOP) compare to VRTX and REGN?
Neurotech International's Shares Outstanding (EOP) of 1,049.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Neurotech International and its competitors. Neurotech International's current Shares Outstanding (EOP) is 1,049.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current Shares Outstanding (EOP) of 1,049.62 Mil. The current Shares Outstanding (EOP) is 1,049.62 Mil. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Neurotech International (NTILF), the current Shares Outstanding (EOP) is 1,049.62 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurotech International Business Description

Other Exchanges NTI:Australia
Address 55 Collins Street, Suite 102, Level 1, Melbourne, VIC, AUS, 3000
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score

Get the complete analysis for NTILF

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price